Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

ClinicalTrials.gov

Author's Posts:
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Conditions:   Amyloidosis;   AL Amyloidosis
Intervention:   Drug: ZN-d5
Sponsor:   K-Group Alpha, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients With Cancer
Condition:   Malignant Solid Neoplasm
Intervention:   Other: Internet-Based Intervention
Sponsor:   Ohio State University Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
Condition:   Lymphoma, Large B-Cell, Diffuse
Intervention:   Behavioral: Digital Health Coaching
Sponsors:   Pack Health;   Novartis;   Ohio State University Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Condition:   Solid Tumor
Intervention:   Drug: 23ME-00610
Sponsor:   23andMe, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Conditions:   Ovarian Cancer;   Ovarian Carcinoma;   Ovary Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: STRO-002;   Drug: Bevacizumab
Sponsor:   Sutro Biopharma, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Conditions:   HER2-positive Breast Cancer;   HER2-positive Gastric Cancer;   HER2-positive Colorectal Cancer;   HER2-expressing Non-small Cell Lung Cancer
Interventions:   Drug: SBT6050;   Drug: trastuzumab deruxtecan;   Drug: tucatinib;   Drug: trastuzumab;   Drug: capecitabine
Sponsor:   Silverback Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Conditions:   Gynecologic Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Non-small Cell Lung Cancer;   Cholangiocarcinoma;   Ovarian Cancer;   Endometrial Cancer;   Ovarian Carcinoma;   Ovary Neoplasm;   Squamous Cell Lung Cancer;   Adenocarcinoma of Lung;   Adenosquamous Cell Lung Cancer
Intervention:   Biological: Neoantigen specific TCR-T cell drug product
Sponsor:   Ziopharm
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
Walnuts and Colon Health
Conditions:   Colorectal Cancer;   Diet Habit
Intervention:   Other: Walnuts
Sponsors:   UConn Health;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Weill Medical College of Cornell University;   University of Connecticut;   The Jackson Laboratory for Genomic Medicine;   California Walnut Commission;   Spanish National Research Council
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Condition:   Glioma
Interventions:   Drug: Pembrolizumab;   Combination Product: Olaparib and Temozolomide
Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements
Condition:   Obesity
Interventions:   Device: GF-IGB: Obalon Balloon;   Dietary Supplement: Medically Supervised Meal Replacement Program: My New Weigh;   Procedure: Endoscopic sleeve gastroplasty: (ESG)
Sponsor:   University of Colorado, Denver
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 19, 2022 / by / in